BALVERSA (erdafitinib) has strong market potential in the FGFR-altered urothelial carcinoma space, particularly as a targeted therapy for patients wi ...
Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...
Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...
Gain-of-function mutations in fibroblast growth factor receptor (FGFR) genes are known to cause a range of skeletal disorders, such as craniosynostosis and chondrodysplasia, which severely affect ...
The research delves into how mutations in FGFR2 and FGFR3 affect mandibular bone formation and endochondral bone repair following non-stabilized fractures. The findings reveal that FGFR ...
The drug is being studied only in those patients with an FGFR mutation. A phase 2 study showed the drug produced an overall response rate of 42% in 59 patients with relapsed/refractory metastatic ...
which maintains efficacy against resistance mutations, shows potency in gastric cancer animal model, and demonstrates a more favorable safety profile compared to existing FGFR inhibitors.
The tumor was negative for BRAF mutation/fusion. Two weeks after biopsy ... We report a case of SCFE, an on-target skeletal toxicity of a pan-FGFR TKI inhibitor, erdafitinib. Central hypothalamic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback